Source-grounded facts extracted from Inmune Bio, Inc.'s SEC 8-K filings across all families, newest first. Each cites a verbatim SEC excerpt.
Inmune Bio, Inc. shareholders approved Approval of the Third Amended and Restated INmune Bio Inc. 2021 Stock Incentive Plan at the 2026-06-16 meeting.
“Proposal Three: Approval of the Third Amended and Restated INmune Bio Inc. 2021 Stock Incentive Plan. As noted above, the stockholders approved the Amended Plan. For Against Abstentions Broker Non-Votes 6,085,086 2,775,224 95,367 8,501,317”
Inmune Bio, Inc. shareholders approved Ratification of Appointment of Independent Auditor at the 2026-06-16 meeting.
“Proposal Two: Ratification of Appointment of Independent Auditor. Stockholders approved the ratification of the appointment of CBIZ CPAs P.C. as the Company’s independent auditors for the fiscal year ending December 31, 2026. For Against Abstentions Broker Non-Votes 17,293,255 107,064 56,675 0”
Inmune Bio, Inc. shareholders approved Election of Directors at the 2026-06-16 meeting.
“Proposal One: Election of Directors. Stockholders elected each of the following nominees as directors to hold office until the next meeting of the Company’s stockholders and until his or her successor is elected and qualified. Nominee Votes For Votes Withheld Broker Non-Votes David Moss 6,834,995 2,120,682 8,501,317 J. Kelly Ganjei 5,955,609 3,000,068 8,501,317 Tim Schroeder 6,622,916 2,332,761 8,501,317 Scott Juda, JD 7,508,310 1,447,367 8,501,317 Marcia Allen 6,342,910 2,612,767 8,501,317 1”
Inmune Bio, Inc. entered into Amended and Restated Material Transfer and License Agreement with Anthony Nolan valued at an annual cap of £5,000,000 (effective 2026-04-29).
“On April 29, 2026, INmune Bio Inc. (the “Company”) entered into an amended and restated Material Transfer and License Agreement (the “ Amended and Restated Agreement ”) with INmune Bio International (“ IMB ”), a company incorporated in England and the Company’s wholly-owned subsidiary, and Anthony Nolan (“ AN ”), a company limited by guarantee incorporated in England, which amended and restated the original agreement signed by IMB and AN on November 29, 2017, as amended and restated on March 21, 2023 (the “ Original Agreement ”).”
Inmune Bio, Inc. amended Warrant Amendment with certain holders of warrants previously issued by the Company valued at $0.05 per April 2024 Warrant, for aggregate proceeds of $67,416 (effective 2025-12-22).
“On December 22, 2025, INmune Bio Inc. (the “Company”) entered into an amendment (the “Warrant Amendment”) with certain holders of warrants previously issued by the Company in its April 2024 offerings”
Inmune Bio, Inc. entered into Sales Agreement with A.G.P./Alliance Global Partners valued at up to $65,000,000 (effective 2025-12-19).
“On December 19, 2025, INmune Bio Inc. (the “Company”) entered into a Sales Agreement (the “Sales Agreement”) with A.G.P./Alliance Global Partners (“A.G.P.”), as sales agent, pursuant to which the Company may offer and sell, from time to time, through A.G.P., up to $65,000,000 of shares of its common stock”
Inmune Bio, Inc. terminated Amended and Restated At-The-Market Sales Agreement with RBC Capital Markets, LLC and BTIG, LLC (effective 2025-12-19).
“On December 5, 2025 and December 9, 2025, pursuant to and in accordance with Section 12(b) of the Sales Agreement, the Company notified RBC and BTIG, respectively, that the Company is terminating the Sales Agreement, effective December 19, 2025.”
Inmune Bio, Inc. amended Rights Agreement with VStock Transfer, LLC (effective 2025-12-05).
“On December 5, 2025, INmune Bio Inc. (the “Company”) entered into Amendment No. 5 (the “Amendment”) to the Rights Agreement, dated as of December 30, 2020, between the Company and VStock Transfer, LLC, as Rights Agent, as amended (the “Rights Agreement”).”
Inmune Bio, Inc. engaged CBIZ CPAs P.C. as its auditor.
“On May 7, 2025, with the approval of the Company’s audit committee, CBIZ CPAs was engaged as the Company’s new independent registered public accounting firm for the fiscal year ending December 31, 2025.”
Inmune Bio, Inc. dismissed Marcum LLP as its auditor.
“On May 7, 2025, INmune Bio Inc. (the “Company”) dismissed Marcum as the Company’s independent registered public accounting firm as a result of such acquisition, and the Company’s audit committee approved the dismissal.”
Edgardo Baracchini resigned as Director at Inmune Bio, Inc..
“On July 5, 2024, Edgardo Baracchini informed INmune Bio Inc. (the “Company”) of his resignation from the board of directors of the Company (the “Board”), effective immediately.”
Inmune Bio, Inc. entered into Placement Agency Agreement with Maxim Group LLC valued at 6% cash fee of gross proceeds (effective 2024-04-24).
“Pursuant to a placement agency agreement (the “Placement Agency Agreement”) dated as of April 24, 2024, between the Company and Maxim Group LLC (the “Placement Agent”), the Company engaged the Placement Agent to act as the Company’s sole placement agent in connection with the registered direct offering.”
Inmune Bio, Inc. entered into Securities Purchase Agreement with Purchasers valued at 986,000 shares of common stock and warrants at $9.84 per share, aggregate gross proceeds $9,702,240 (effective 2024-04-24).
“On April 24, 2024, INmune Bio, Inc. (the “Company”), entered into a securities purchase agreement (the “Purchase Agreement”) with the purchaser set forth on the signature page thereto (the “Purchasers) for the purchase and sale of an aggregate of 986,000 shares of the Company’s common stock (the “Shares”) and common stock warrants to purchase 986,000 shares of its common stock (“Warrants”) in a registered direct offering.”
Inmune Bio, Inc. entered into Placement Agency Agreement with LifeSci Capital LLC valued at Cash fee equal to 4% of gross proceeds from sale of shares and warrants (effective 2024-04-19).
“Pursuant to a placement agency agreement (the “Placement Agency Agreement”) dated as of April 19, 2024, between the Company and LifeSci Capital LLC (the “Placement Agent Agreement,” the Company engaged the Placement Agent to act as the Company’s sole placement agent in connection with the registered direct offering.”
Inmune Bio, Inc. entered into Securities Purchase Agreement with Purchasers valued at 571,592 shares of common stock and warrants to purchase 571,592 shares at $8.32 per share and warran (effective 2024-04-19).
“On April 19, 2024, INmune Bio, Inc. (the “Company”), entered into a securities purchase agreement (the “Purchase Agreement”) with the purchasers set forth on the signature page thereto (the “Purchasers”) for the purchase and sale of an aggregate of 571,592 shares of the Company’s common stock (the “Shares”) and common stock warrants to purchase 571,592 shares of its common stock (“Warrants”) in a registered direct offering.”
Inmune Bio, Inc. reported the year ended December 31, 2023 results: net income approximately $30.0 million.
“Net loss attributable to common stockholders for the year ended December 31, 2023, was approximately $30.0 million, compared to approximately $27.3 million during the year ended December 31, 2022.”
Inmune Bio, Inc. amended Amendment No. 3 to the Rights Agreement with VStock Transfer, LLC (effective 2023-12-14).
“On December 14, 2023, the Company and VStock Transfer, LLC entered into Amendment No. 3 to the Rights Agreement ("Amendment No. 3").”
Inmune Bio, Inc. reported financial results for the quarter ended September 30, 2023.
“On November 1, 2023, INmune Bio Inc. (the “Company”), issued a press release announcing the Company’s financial results for the quarter ended September 30, 2023 and providing a business update.”
Inmune Bio, Inc. reported financial results for quarter ended June 30, 2023.
“On August 7, 2023, INmune Bio Inc. (the “Company”) issued a press release announcing its financial results for the quarter ended June 30, 2023”
Inmune Bio, Inc. reported the quarter ended March 31, 2023 results: net income approximately $6.5 million.
“Net loss attributable to common stockholders for the quarter ended March 31, 2023 was approximately $6.5 million, compared to approximately $6.9 million during the quarter ended March 31, 2022.”
Inmune Bio, Inc. amended Second PITT Amendment with University of Pittsburgh (effective 2023-04-17).
“On April 17, 2023, the Company entered into the Second Amendment to Exclusive License Agreement to the PITT Agreement (the “Second PITT Amendment”).”
Inmune Bio, Inc. amended INKmune Amendment with Immune Ventures, LLC (effective 2023-04-17).
“On April 17, 2023, the Company entered into an additional amendment to the INKmune License Agreement (the “INKmune Amendment”) to remove the due diligence requirements of the INKmune License Agreement, including using reasonable commercial efforts to bring licensed products and services to market, removing all initiation of clinical trial requirements, and the filing of an NDA or equivalent upon successful completion of Phase III clinical trials.”
Inmune Bio, Inc. reported financial results for the year ended December 31, 2022.
“INmune Bio, Inc. (NASDAQ: INMB) (the “Company”), a clinical-stage immunology company focused on developing treatments that harness the patient’s innate immune system to fight disease, today announces its financial results for the year ended December 31, 2022 and provides a business update.”
Inmune Bio, Inc. amended Amendment No. 2 to Rights Agreement with VStock Transfer, LLC (effective 2022-12-09).
“On December 9, 2022, the Company and VStock Transfer, LLC entered into Amendment No. 2 to Rights Agreement (“Amendment No. 2”).”
Inmune Bio, Inc. reported the quarter ended September 30, 2022 results: net income approximately $7.7 million.
“Net loss attributable to common stockholders for the quarter ended September 30, 2022 was approximately $7.7 million, compared to approximately $9.5 million for the quarter ended September 30, 2021.”
Facts are extracted by an LLM and gated to those whose source quote is present verbatim in the filing text. Coverage is best-effort while backfill and monitoring mature; this is not yet a full-market index. See methodology.